相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells
Dalal AlSultan et al.
INVESTIGATIONAL NEW DRUGS (2021)
The new role for an old guy: MYC as an immunoplayer
Dragan Marinkovic et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2021)
Microhomology-mediated end joining drives complex rearrangements and overexpression of MYC and PVT1 in multiple myeloma
Aneta Mikulasova et al.
HAEMATOLOGICA (2020)
Recent insight into the role of FBXW7 as a tumor suppressor
Kanae Yumimoto et al.
SEMINARS IN CANCER BIOLOGY (2020)
MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype
Nicole M. Sodir et al.
CANCER DISCOVERY (2020)
Discovery of WD Repeat-Containing Protein 5 (WDR5)-MYC Inhibitors Using Fragment-Based Methods and Structure-Based Design
Selena Chacon Simon et al.
JOURNAL OF MEDICINAL CHEMISTRY (2020)
Blocking Myc to Treat Cancer: Reflecting on Two Decades of Omomyc
Daniel Masso-Valles et al.
CELLS (2020)
Structural and Biophysical Insights into the Function of the Intrinsically Disordered Myc Oncoprotein
Marie-Eve Beaulieu et al.
CELLS (2020)
The Myc and Ras Partnership in Cancer: Indistinguishable Alliance or Contextual Relationship?
Wadie D. Mahauad-Fernandez et al.
CANCER RESEARCH (2020)
Human MYC G-quadruplex: From discovery to a cancer therapeutic target
Wenmeng Wang et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2020)
c-MYC Drives Breast Cancer Metastasis to the Brain, but Promotes Synthetic Lethality with TRAIL
Ho Yeon Lee et al.
MOLECULAR CANCER RESEARCH (2019)
Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers
Edina Wang et al.
ONCOGENE (2019)
Recent Progress of Targeted G-Quadruplex-Preferred Ligands Toward Cancer Therapy
Sefan Asamitsu et al.
MOLECULES (2019)
Intrinsic cell-penetrating activity propels Omomyc from proof of concept to viable anti-MYC therapy
Marie-Eve Beaulieu et al.
SCIENCE TRANSLATIONAL MEDICINE (2019)
c-MYC regulates mRNA translation efficiency and start-site selection in lymphoma
Kamini Singh et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2019)
Omomyc Reveals New Mechanisms To Inhibit the MYC Oncogene
Mark J. Demma et al.
MOLECULAR AND CELLULAR BIOLOGY (2019)
Interaction of the oncoprotein transcription factor MYC with its chromatin cofactor WDR5 is essential for tumor maintenance
Lance R. Thomas et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2019)
Direct Targeting of MYCN Gene Amplification by Site-Specific DNA Alkylation in Neuroblastoma
Hiroyuki Yoda et al.
CANCER RESEARCH (2019)
Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas
Tianjin Yi et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Translation control of the immune checkpoint in cancer and its therapeutic targeting
Yichen Xu et al.
NATURE MEDICINE (2019)
The MYC oncogene is a global regulator of the immune response
Stephanie C. Casey et al.
BLOOD (2018)
APTO-253 Stabilizes G-quadruplex DNA, Inhibits MYC Expression, and Induces DNA Damage in Acute Myeloid Leukemia Cells
Andrea Local et al.
MOLECULAR CANCER THERAPEUTICS (2018)
APTO-253 Is a New Addition to the Repertoire of Drugs that Can Exploit DNA BRCA1/2 Deficiency
Cheng-Yu Tsai et al.
MOLECULAR CANCER THERAPEUTICS (2018)
MYCN acts as a direct co-regulator of p53 in MYCN amplified neuroblastoma
Saurabh Agarwal et al.
Oncotarget (2018)
A selective high affinity MYC-binding compound inhibits MYC: MAX interaction and MYC-dependent tumor cell proliferation
Alina Castell et al.
SCIENTIFIC REPORTS (2018)
The MYC transcription factor network: balancing metabolism, proliferation and oncogenesis
Patrick A. Carroll et al.
FRONTIERS OF MEDICINE (2018)
MYC Interacts with the G9a Histone Methyltransferase to Drive Transcriptional Repression and Tumorigenesis
William B. Tu et al.
CANCER CELL (2018)
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer
Jason. P. W. Carey et al.
CANCER RESEARCH (2018)
OmoMYC blunts promoter invasion by oncogenic MYC to inhibit gene expression characteristic of MYC-dependent tumors
L. A. Jung et al.
ONCOGENE (2017)
Integrative analysis of RNA polymerase II and transcriptional dynamics upon MYC activation
Stefano de Pretis et al.
GENOME RESEARCH (2017)
Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth
L. C. Lustig et al.
ONCOGENE (2017)
MB0 and MBI Are Independent and Distinct Transactivation Domains in MYC that Are Essential for Transformation
Qin Zhang et al.
GENES (2017)
MYC Deregulation in Primary Human Cancers
Manpreet Kalkat et al.
GENES (2017)
Strategies to Inhibit Myc and Their Clinical Applicability
Jonathan R. Whitfield et al.
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2017)
Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers
Markus Schick et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
BET inhibitors: a novel epigenetic approach
D. B. Doroshow et al.
ANNALS OF ONCOLOGY (2017)
KLF4 expression enhances the efficacy of chemotherapy drugs in ovarian cancer cells
Baojin Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2017)
Interaction of MYC with host cell factor-1 is mediated by the evolutionarily conserved Myc box IV motif
L. R. Thomas et al.
ONCOGENE (2016)
Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression
Tikvah K. Hayes et al.
CANCER CELL (2016)
Clinical and Biologic Significance of MYC Genetic Mutations in De Novo Diffuse Large B-cell Lymphoma
Zijun Y. Xu-Monette et al.
CLINICAL CANCER RESEARCH (2016)
PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression
Dai Horiuchi et al.
NATURE MEDICINE (2016)
MYC regulates the antitumor immune response through CD47 and PD-L1
Stephanie C. Casey et al.
SCIENCE (2016)
Cyclin-dependent kinase inhibitors for the treatment of chronic lymphocytic leukemia
James S. Blachly et al.
SEMINARS IN ONCOLOGY (2016)
MYC/MIZ1-dependent gene repression inversely coordinates the circadian clock with cell cycle and proliferation
Anton Shostak et al.
NATURE COMMUNICATIONS (2016)
Oncogenic regulation of tumor metabolic reprogramming
Miriam Tarrado-Castellarnau et al.
ONCOTARGET (2016)
Different promoter affinities account for specificity in MYC-dependent gene regulation
Francesca Lorenzin et al.
ELIFE (2016)
Small-molecule inhibitors of the Myc oncoprotein
Steven Fletcher et al.
BIOCHIMICA ET BIOPHYSICA ACTA-GENE REGULATORY MECHANISMS (2015)
CDK7-Dependent Transcriptional Addiction in Triple-Negative Breast Cancer
Yubao Wang et al.
CELL (2015)
Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors
Andrea Cercek et al.
INVESTIGATIONAL NEW DRUGS (2015)
Targeting Translation Initiation Bypasses Signaling Crosstalk Mechanisms That Maintain High MYC Levels in Colorectal Cancer
Armin Wiegering et al.
CANCER DISCOVERY (2015)
Targeting MYC Translation in Colorectal Cancer
Alina Castell et al.
CANCER DISCOVERY (2015)
Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery
Lei-lei Fu et al.
ONCOTARGET (2015)
Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor
Camilla L. Christensen et al.
CANCER CELL (2014)
CDK7 Inhibition Suppresses Super-Enhancer-Linked Oncogenic Transcription in MYCN-Driven Cancer
Edmond Chipumuro et al.
CELL (2014)
The Mechanisms behind the Therapeutic Activity of BET Bromodomain Inhibition
Junwei Shi et al.
MOLECULAR CELL (2014)
Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis
Arianna Sabo et al.
NATURE (2014)
Activation and repression by oncogenic MYC shape tumour-specific gene expression profiles
Susanne Walz et al.
NATURE (2014)
Targeting of the MYCN Protein with Small Molecule c-MYC Inhibitors
Inga Muller et al.
PLOS ONE (2014)
Inhibitor of MYC identified in a Krohnke pyridine library
Jonathan R. Hart et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
An Overview of MYC and Its Interactome
Maralice Conacci-Sorrell et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2014)
BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic Therapy
Miguel F. Segura et al.
CANCER RESEARCH (2013)
Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice
Laura Soucek et al.
GENES & DEVELOPMENT (2013)
MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells
Hanna Zirath et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition
Dai Horiuchi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2012)
Myc, Aurora Kinase A, and mutant p53R172H co-operate in a mouse model of metastatic skin carcinoma
E. C. Torchia et al.
ONCOGENE (2012)
Sensitivity of human lung adenocarcinoma cell lines to targeted inhibition of BET epigenetic signaling proteins
William W. Lockwood et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake E. Delmore et al.
CELL (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson et al.
NATURE (2011)
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms
Pixu Liu et al.
NATURE MEDICINE (2011)
The Action Mechanism of the Myc Inhibitor Termed Omomyc May Give Clues on How to Target Myc for Cancer Therapy
Mauro Savino et al.
PLOS ONE (2011)
Targeting MYC dependence in cancer by inhibiting BET bromodomains
Jennifer A. Mertz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
A β-catenin/TCF-coordinated chromatin loop at MYC integrates 5′ and 3′ Wnt responsive enhancers
Gregory S. Yochum et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
Dun Yang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z,E]-5-[4-ethylbenzylidine]-2-thioxothiazolidin-4-one, in mice
Jianxia Guo et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Discovery of Novel Myc-Max Heterodimer Disruptors with a Three-Dimensional Pharmacophore Model
Gabriela Mustata et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
A novel small molecule with potent anticancer activity inhibits cell growth by modulating intracellular labile zinc homeostasis
Mario Huesca et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Stabilizers of the Max Homodimer Identified in Virtual Ligand Screening Inhibit Myc Function
Hao Jiang et al.
MOLECULAR PHARMACOLOGY (2009)
Distinct Thresholds Govern Myc's Biological Output In Vivo
Daniel J. Murphy et al.
CANCER CELL (2008)
Structural Rationale for the Coupled Binding and Unfolding of the c-Myc Oncoprotein by Small Molecules
Ariele Viacava Follis et al.
CHEMISTRY & BIOLOGY (2008)
Modelling Myc inhibition as a cancer therapy
Laura Soucek et al.
NATURE (2008)
MYC - TIMELINE Reflecting on 25 years with MYC
Natalie Meyer et al.
NATURE REVIEWS CANCER (2008)
Improved low molecular weight Myc-Max inhibitors
Huabo Wang et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Non-transcriptional control of DNA replication by c-Myc
David Dominguez-Sola et al.
NATURE (2007)
Inhibition of CDK1 as a potential therapy for tumors over-expressing MYC
Andrei Goga et al.
NATURE MEDICINE (2007)
Novel c-MYC target genes mediate differential effects on cell proliferation and migration
David Cappellen et al.
EMBO REPORTS (2007)
Global mapping of c-Myc binding sites and target gene networks in human B cells
Karen I. Zeller et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
A conserved Myc protein domain, MBIV, regulates DNA binding, apoptosis, transformation, an G2 arrest
Victoria H. Cowling et al.
MOLECULAR AND CELLULAR BIOLOGY (2006)
c-Myc binds to human ribosomal DNA and stimulates transcription of rRNA genes by RNA polymerase I
C Grandori et al.
NATURE CELL BIOLOGY (2005)
A conserved element in Myc that negatively regulates its proapoptotic activity
A Herbst et al.
EMBO REPORTS (2005)
Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7
M Yada et al.
EMBO JOURNAL (2004)
Low molecular weight inhibitors of Myc-Max interaction and function
XY Yin et al.
ONCOGENE (2003)
A global transcriptional regulatory role for c-Myc in Burkitt's lymphoma cells
ZR Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Genomic targets of the human c-Myc protein
PC Fernandez et al.
GENES & DEVELOPMENT (2003)
Direct activation of RNA polymerase III transcription by c-Myc
N Gomez-Roman et al.
NATURE (2003)
Sustained loss of a neoplastic phenotype by brief inactivation of MYC
M Jain et al.
SCIENCE (2002)
The Max network gone mad
TA Baudino et al.
MOLECULAR AND CELLULAR BIOLOGY (2001)
分享论文
